Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters - PubMed (original) (raw)

Review

Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters

L J Ignarro. Pharm Res. 1989 Aug.

Abstract

Vascular smooth muscle relaxation elicited by various endogenous substances results from their interaction with vascular endothelial cells to triger the formation of endothelium-derived relaxing factor (EDRF). EDRF from pulmonary and peripheral arteries and veins and from cultured and freshly harvested aortic endothelial cells has been identified pharmacologically and chemically as nitric oxide (NO) or a labile nitroso compound. Endothelium-derived NO (EDNO) and authentic NO activate the cytoplasmic form of guanylate cyclase by heme-dependent mechanism and thereby stimulate intracellular cyclic GMP accumulation in cells including vascular smooth muscle and platelets. Cyclic GMP functions as a second messenger to cause vascular muscle relaxation and inhibition of platelet aggregation and adhesion to vascular endothelial surfaces. EDNO is synthesized from L-arginine and perhaps arginine-containing peptides by an unidentified calcium-requiring process coupled to the occupation of extracellular endothelial receptors. The biological actions of EDNO are terminated by spontaneous oxidation to NO2- and NO3-. The biological half-life of the very lipophilic EDNO is only 3-5 sec and this allows EDNO to function locally as an autacoid. Nitroglycerin and other organic nitrate esters elicit endothelium-independent relaxation after entering vascular smooth muscle cells and undergoing denitration and formation of NO. The pharmacological actions of nitroglycerin are therefore essentially the same as those of EDNO, and the endogenous NO receptor is the heme group bound to soluble guanylate cyclase. EDNO may serve a biological role to modulate local blood flow and platelet function.

PubMed Disclaimer

Cited by

Regulation of platelet granule exocytosis by S-nitrosylation.
Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ, Bergmeier W, Mankowski JL, Baldwin WM 3rd, Faraday N, Lowenstein CJ. Morrell CN, et al. Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3782-7. doi: 10.1073/pnas.0408310102. Epub 2005 Feb 28. Proc Natl Acad Sci U S A. 2005. PMID: 15738422 Free PMC article.
Changes in energy metabolism and X-ray sensitivity in murine tumours by the nitric oxide donor SIN-1.
Wood PJ, Sansom JM, Stratford IJ, Adams GE, Szabo C, Thiemermann C, Vane JR. Wood PJ, et al. Br J Cancer Suppl. 1996 Jul;27:S177-80. Br J Cancer Suppl. 1996. PMID: 8763875 Free PMC article.
Gold nanoparticle modifies nitric oxide release and vasodilation in rat aorta.
Silva BR, Lunardi CN, Araki K, Biazzotto JC, Da Silva RS, Bendhack LM. Silva BR, et al. J Chem Biol. 2014 Mar 23;7(2):57-65. doi: 10.1007/s12154-014-0109-x. eCollection 2014 Apr. J Chem Biol. 2014. PMID: 24711859 Free PMC article.
Nitrates and nitrites in the treatment of ischemic cardiac disease.
Nossaman VE, Nossaman BD, Kadowitz PJ. Nossaman VE, et al. Cardiol Rev. 2010 Jul-Aug;18(4):190-7. doi: 10.1097/CRD.0b013e3181c8e14a. Cardiol Rev. 2010. PMID: 20539102 Free PMC article. Review.
Integrated analysis of transcript-level regulation of metabolism reveals disease-relevant nodes of the human metabolic network.
Galhardo M, Sinkkonen L, Berninger P, Lin J, Sauter T, Heinäniemi M. Galhardo M, et al. Nucleic Acids Res. 2014 Feb;42(3):1474-96. doi: 10.1093/nar/gkt989. Epub 2013 Nov 5. Nucleic Acids Res. 2014. PMID: 24198249 Free PMC article.

References

1. Annu Rev Pharmacol Toxicol. 1984;24:175-97 - PubMed
1. Proc Natl Acad Sci U S A. 1988 Nov;85(22):8664-7 - PubMed
1. Am J Physiol. 1986 May;250(5 Pt 2):H822-7 - PubMed
1. Proc Natl Acad Sci U S A. 1987 Sep;84(18):6369-73 - PubMed
1. Biochemistry. 1988 Nov 29;27(24):8706-11 - PubMed

Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic nitrate esters - PubMed (original) (raw)